Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Kronos Bio, Inc. (KRON)
|
Add to portfolio |
|
|
|
| Price: |
$13.69
| | Metrics |
| OS: |
58.3
|
M
| |
-59
|
% ROE
|
| Market cap: |
$798
|
M
| |
-65
|
% ROIC
|
|
Net cash:
|
$220
|
M
| |
$3.77
|
per share
|
|
EV:
|
$579
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($126)
|
M
| |
|
|
|
EBIT
|
($128)
|
M
| |
|
|
| EPS |
($2.12)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-05-19 | Dec-31-18 | Dec-05-18 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 13.4 | 0.0 | 5.0 |
| Revenue growth | | | | | 167.2% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 16.8 | 0.0 | 6.6 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | -3.4 | 0.0 | -1.6 |
| Gross margin | | | | | -25.1% | | -32.0% |
| Research and development | 93.7 | 112.9 | 43.3 | 13.4 | | 5.0 | |
| General and administrative | 43.4 | 38.5 | 14.8 | 3.4 | 3.4 | 1.6 | 1.6 |
| EBIT | -137.1 | -151.4 | -58.0 | -16.8 | -16.8 | -6.6 | -6.6 |
| EBIT margin | | | | | -125.1% | | -132.0% |
| Pre-tax income | -133.2 | -151.1 | -88.4 | -16.1 | -16.1 | -6.7 | -6.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -133.2 | -151.1 | -88.4 | -16.1 | -16.1 | -6.7 | -6.7 |
| Net margin | | | | | -119.9% | | -133.5% |
| |
| Diluted EPS | ($2.37) | ($2.76) | ($5.43) | ($3.05) | ($3.05) | ($1.38) | ($1.38) |
| Shares outstanding (diluted) | 56.2 | 54.8 | 16.3 | 5.3 | 5.3 | 4.9 | 4.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|